Anavex Life Sciences Corp.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Terrie Kellmeyer
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 630 5th Avenue New York City NY United States of America 10111
- IPO Date
- Aug 2, 2006
- CIK
- 0001314052
- Website
- anavex.com
- Similar Companies
- Business
- Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule therapeutics for the treatment of central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson’s disease dementia, schizophrenia, and rare neurodevelopmental disorders such as Rett syndrome. The company's core product is ANAVEX®2-73 (blarcamesine), an orally available Sigma-1 receptor (SIGMAR1) and muscarinic receptor agonist designed to restore cellular homeostasis by targeting protein misfolding, mitochondrial dysfunction, and autophagy processes. Anavex’s precision medicine platform leverages proprietary SIGMACEPTOR™ technology to develop scalable treatments that potentially modify disease progression across a range of neurodegenerative and neurodevelopmental disorders. The company’s clinical pipeline includes completion of multiple Phase 2 and Phase 3 trials for ANAVEX®2-73 in Alzheimer's disease, Parkinson’s disease dementia, and Rett syndrome, with ongoing plans for further pivotal studies including schizophrenia-related disorders. Recently, Anavex has entered a strategic partnership with Partex NV, leveraging Partex’s proprietary artificial intelligence technology to enhance its precision medicine drug development platform and patient experience ecosystem, extending beyond R&D into healthcare sales and marketing. In 2025, Anavex reported positive clinical trial results demonstrating continued long-term benefit of oral blarcamesine in early Alzheimer's disease patients with notable cognitive and biomarker improvements compared to natural history controls. The company is actively pursuing regulatory re-examination following a negative initial opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the marketing authorization application for blarcamesine. Other ongoing development milestones include advancing ANAVEX®3-71 for schizophrenia-related disorders and designing Phase 2/3 trials for Fragile X syndrome. Anavex maintains a commitment to precision medicine approaches and patient-centric innovation across its geographic operations primarily focused in the United States and Europe. Founded in 2005 and headquartered in New York, Anavex Life Sciences operates as a publicly traded company listed on NASDAQ under the ticker AVXL. The company targets underserved patient populations with high unmet medical needs in neurodegenerative and neurodevelopmental CNS disorders, aiming to bring novel treatment paradigms through its orally administered small molecule therapies. This description reflects the company's current product focus, strategic alliances, regulatory activities, clinical pipeline developments, and operational status as of late 2025.
Company News
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.'s 2026 Annual Meeting
Anavex Life Sciences (AVXL) Sees Stock Surge Following Q3 Update and Regulatory Progress
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Provides Comprehensive Regulatory Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference